Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials.

Corponi F, Serretti A, Montgomery S, Fabbri C.

Int Clin Psychopharmacol. 2017 Jul 19. doi: 10.1097/YIC.0000000000000189. [Epub ahead of print]

PMID:
28727644
2.

The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study.

Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S.

Eur Neuropsychopharmacol. 2017 Jul;27(7):625-632. doi: 10.1016/j.euroneuro.2017.05.004. Epub 2017 May 31.

PMID:
28579072
3.

Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study.

Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S.

J Psychiatr Res. 2017 Aug;91:1-13. doi: 10.1016/j.jpsychires.2017.02.020. Epub 2017 Feb 27.

PMID:
28284107
4.

Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.

Fabbri C, Crisafulli C, Calati R, Albani D, Forloni G, Calabrò M, Martines R, Kasper S, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Serretti A.

Eur Arch Psychiatry Clin Neurosci. 2017 Mar 4. doi: 10.1007/s00406-017-0766-1. [Epub ahead of print]

PMID:
28260126
5.

A New Prediction Model for Evaluating Treatment-Resistant Depression.

Kautzky A, Baldinger-Melich P, Kranz GS, Vanicek T, Souery D, Montgomery S, Mendlewicz J, Zohar J, Serretti A, Lanzenberger R, Kasper S.

J Clin Psychiatry. 2017 Feb;78(2):215-222. doi: 10.4088/JCP.15m10381.

PMID:
28068461
6.

Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study.

Dold M, Kautzky A, Bartova L, Rabl U, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S.

Eur Neuropsychopharmacol. 2016 Dec;26(12):1960-1971. doi: 10.1016/j.euroneuro.2016.10.005. Epub 2016 Nov 2.

PMID:
27816317
7.

Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis.

Montgomery SA, Lyndon G, Almas M, Whalen E, Prieto R.

Int Clin Psychopharmacol. 2017 Jan;32(1):41-48.

PMID:
27583543
8.

Are the ICD-10 or DSM-5 diagnostic systems able to define those who will benefit from treatment for depression?

Montgomery S.

CNS Spectr. 2016 Aug;21(4):283-8. doi: 10.1017/S1092852916000389. Epub 2016 Jul 15.

PMID:
27418397
9.

Bipolar II disorder as a risk factor for postpartum depression.

Mandelli L, Souery D, Bartova L, Kasper S, Montgomery S, Zohar J, Mendlewicz J, Serretti A.

J Affect Disord. 2016 Nov 1;204:54-8. doi: 10.1016/j.jad.2016.06.025. Epub 2016 Jun 14.

PMID:
27327115
10.

High occupational level is associated with poor response to treatment of depression.

Mandelli L, Serretti A, Souery D, Mendlewicz J, Kasper S, Montgomery S, Zohar J.

Eur Neuropsychopharmacol. 2016 Aug;26(8):1320-6. doi: 10.1016/j.euroneuro.2016.05.002. Epub 2016 Jul 7.

PMID:
27211903
11.

Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.

Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I, Fava M, Montgomery SA.

J Clin Psychiatry. 2016 Mar;77(3):371-8. doi: 10.4088/JCP.15m10070.

12.

The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment--a European multicentre study.

Höfer P, Schosser A, Calati R, Serretti A, Massat I, Kocabas NA, Konstantinidis A, Mendlewicz J, Souery D, Zohar J, Juven-Wetzler A, Montgomery S, Kasper S.

Int Clin Psychopharmacol. 2016 Jan;31(1):1-7. doi: 10.1097/YIC.0000000000000101.

PMID:
26544898
13.

Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study.

Balestri M, Calati R, Souery D, Kautzky A, Kasper S, Montgomery S, Zohar J, Mendlewicz J, Serretti A.

J Affect Disord. 2016 Jan 1;189:224-32. doi: 10.1016/j.jad.2015.09.033. Epub 2015 Sep 30.

PMID:
26451508
14.

Antidepressant or antidepressant plus placebo effect?

Montgomery SA.

World Psychiatry. 2015 Oct;14(3):303-4. doi: 10.1002/wps.20244. No abstract available.

15.

Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression.

Zaninotto L, Souery D, Calati R, Di Nicola M, Montgomery S, Kasper S, Zohar J, Mendlewicz J, Robert Cloninger C, Serretti A, Janiri L.

J Affect Disord. 2015 Sep 15;184:51-9. doi: 10.1016/j.jad.2015.05.036. Epub 2015 May 28.

PMID:
26070046
16.

Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample.

Zaninotto L, Souery D, Calati R, Camardese G, Janiri L, Montgomery S, Kasper S, Zohar J, De Ronchi D, Mendlewicz J, Serretti A.

Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):48-52. doi: 10.9758/cpn.2015.13.1.48.

17.

The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression.

Kautzky A, Baldinger P, Souery D, Montgomery S, Mendlewicz J, Zohar J, Serretti A, Lanzenberger R, Kasper S.

Eur Neuropsychopharmacol. 2015 Apr;25(4):441-53. doi: 10.1016/j.euroneuro.2015.01.001. Epub 2015 Feb 2.

PMID:
25769916
18.

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.

Wang G, Gislum M, Filippov G, Montgomery S.

Curr Med Res Opin. 2015 Apr;31(4):785-94. doi: 10.1185/03007995.2015.1014028. Epub 2015 Feb 19.

PMID:
25650503
19.

What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.

Souery D, Calati R, Papageorgiou K, Juven-Wetzler A, Gailledreau J, Modavi D, Sentissi O, Pitchot W, Papadimitriou GN, Dikeos D, Montgomery S, Kasper S, Zohar J, Serretti A, Mendlewicz J.

World J Biol Psychiatry. 2015 Oct;16(7):472-82. doi: 10.3109/15622975.2014.987814. Epub 2014 Dec 23.

PMID:
25535987
20.

Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates.

Zaninotto L, Souery D, Calati R, Scudellari P, Janiri L, Montgomery S, Kasper S, Zohar J, Mendlewicz J, Serretti A.

Ann Clin Psychiatry. 2014 Nov;26(4):243-53.

PMID:
25166487

Supplemental Content

Loading ...
Support Center